Date: January 19, 2021
Time: 8:00am (PST), 11:00am (EST)
Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Research has shown that additional mechanisms of inhibition prevent the majority of patients from successful treatment. Recent studies into the inhibitory role of macrophages portend that these cells are associated with lower survival rate in several different cancer types. In this webinar, Immunologist Prof. Dr. Elfriede Nößner will present her research on specific macrophages in RCC (“ercDCs”) which are associated with poor outcome and their potential as new targets in immune therapy.
- What is known about the role of macrophages in immuno-oncology in general and in RCC specifically
- What are “ercDCs” and how do they interact with T-Cells in RCC?
- Which possibilities exist to manipulate the ercDCs?
Webinars will be available for unlimited on-demand viewing after live event.